1887
  1. Home
  2. A-Z Publications
  3. Journal of Emergency Medicine, Trauma and Acute Care
  4. Volume 2024, Issue 6
  5. Article
6 - Al-Bayan University Scientific Conference
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

This study demonstrates the potential of sulindac to enhance resistance to tumor proliferation by both blocking tumor-induced immune suppression and stopping the growth of oral tumors. In contrast to adriamycin, sulindac significantly reduces the release of vascular endothelial growth factor (VEGF) and IL-6 from tumor cells by downregulating the NFκB and JNK signaling pathways. Additionally, it reduces the simultaneously induced production of VEGF and IL-6 during contacts between immune cells and tumors. Furthermore, sulindac dramatically reduces VEGF levels in the presence of IL-2-stimulated NK cells, indicating an improved immune response against tumor cells. Even the immunological suppression caused by tumor cells stimulated with TNF-α is reversed by sulindac. Consequently, the combination of sulindac with chemotherapy can effectively inhibit tumor growth and increase resistance to oral malignancies.

© 2024 Raheem, Ali, Jassim, Hasan, Jasem, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2024.absc.10
2024-10-20
2024-12-05
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2024/6/jemtac.2024.absc.10.html?itemId=/content/journals/10.5339/jemtac.2024.absc.10&mimeType=html&fmt=ahah

References

  1. Rashid G, Khan NA, Elsori D, Rehman A, Tanzeelah , Ahmad H, et al. Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer. Front Med (Lausanne). 2023 Mar 6;10:1130710. doi: 10.3389/fmed.2023.1130710. PMID: 36950511; PMCID: PMC10025514.
     [Google Scholar]
  2. Castelao JE, Yuan J-M, Gago-Dominguez M, Yu MC, Ross RK . Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 2000;82:(7):1364–9. doi: 10.1054/bjoc.1999.1106.
     [Google Scholar]
  3. Grilli M, Pizzi M, Memo M, Spano P . Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science. 1996 Nov 22; 274:(5291):1383–5. doi: 10.1126/science.274.5291.1383.
     [Google Scholar]
  4. Jewett A, Cacalano NA, Teruel A, Romero M, Rashedi M, Wang M, et al. Inhibition of nuclear factor kappa B (NFkappaB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation. Cancer Immunol Immunother. 2006 Sep; 55:(9):1052–63. doi: 10.1007/s00262-005-0093-7. Epub 2005 Nov 18. PMID: 16328384.
     [Google Scholar]
  5. Kamimura D, Ishihara K, Hirano T . IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 2018;149:1–38. doi: 10.1007/s10254-003-0012-2.
     [Google Scholar]
  6. Mah AY, Cooper MA . Metabolic regulation of natural killer cell IFN-γ production. Crit Rev Immunol. 2016; 36:(2):131–47. doi: 10.1615/CritRevImmunol.2016017387. PMID: 27910764; PMCID: PMC5335907.
     [Google Scholar]
  7. Brasier AR . The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res. 2010 May 1; 86:(2):211–8. doi: 10.1093/cvr/cvq076. Epub 2010 Mar 3. PMID: 20202975; PMCID: PMC2912657.
     [Google Scholar]
  8. Hibi M, Lin A, Smeal T, Minden A, Karin M . Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c- Jun activation domain. Genes Dev. 1993 Nov; 7:(11):2135–48. doi: 10.1101/gad.7.11.2135.
     [Google Scholar]
  9. Laha D, Grant R, Mishra P, Nilubol N . The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment. Front Immunol. 2021 Apr 27;12:656908. doi: 10.3389/fimmu.2021.656908. PMID: 33986746; PMCID: PMC8110933.
     [Google Scholar]
  10. Dhanasekaran DN, Reddy EP . JNK signaling in apoptosis. Oncogene. 2008 Oct 20; 27:(48):6245-51. doi: 10.1038/onc.2008.301. PMID: 18931691; PMCID: PMC3063296.
     [Google Scholar]
  11. Chen F . JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res. 2012 Jan 15; 72:(2):379-86. doi: 10.1158/0008-5472.CAN-11-1982. PMID: 22253282; PMCID: PMC3261582.
     [Google Scholar]
  12. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB . Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999 Sep 17; 274:(38):27307–14. doi: 10.1074/jbc.274.38.27307. PMID: 10480951.
     [Google Scholar]
  13. Li X, Pathi SS, Safe S . Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors. BMC Cancer. 2015 Dec 16;15:974. doi: 10.1186/s12885-015-1956-8. PMID: 26673922; PMCID: PMC4682223.
     [Google Scholar]
  14. Jewett A, Bonavida B . Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol. 1996 Feb 1; 156:(3):907-15. doi: 10.4049/jimmunol.156.3.907.
     [Google Scholar]
  15. Sjaastad FV, Swanson W, Griffith TS . JoVE science education database. Immunology. Assay for Cell Death: Chromium Release Assay of Cytotoxic Ability. Cambridge, MA: JoVE (2023).
     [Google Scholar]
  16. Berman KS, Verma UN, Harburg G, Minna JD, Cobb MH, Gaynor RB . Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin Cancer Res. 2022 Feb;8(2):354–60.
     [Google Scholar]
  17. Giardiello FM, Spannhake EW, DuBois RN, Hylind LM, Robinson CR, Hubbard WC, et al. Prostaglandin levels in human colorectal mucosa: Effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci. 1998 Feb; 43:(2):311–6. doi: 10.1023/a:1018898120673.
     [Google Scholar]
  18. Esra Hassan AA, Suzan MAR . Gingival and salivary changes in correlation with multiple sclerosis, Medico-Legal Update. 2020 Jan–Mar; 20:(1);739–45. doi:10.37506/v20/il/2020/mlu/194413.
     [Google Scholar]
  19. Al-zahraa JJ, Zainab AA . Evaluation of mutans streptococci concerning oral health in the saliva of pregnant women. Revis Bionatura. 2023;8(2)81. doi: 10.21931/RB/2023.08.02.81.
     [Google Scholar]
  20. Diehl S, Rincon M . The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002 Dec; 39:(9):531–36. doi: 10.1016/s0161-5890(02)00210-9.
     [Google Scholar]
  21. Yin T, Wang G, Ye T, Wang Y. Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator. Sci Rep. 2016 Jan 18;6:19534. doi: 10.1038/srep19534. PMID: 26777116; PMCID: PMC4725989.
     [Google Scholar]
  22. Lee HH, Kang H, Cho H . Role of interleukin(IL)-6 in NK activity to hypoxic-induced highly invasive hepatocellular carcinoma(HCC) cells. J Microbiol Biotechnol. 2023 Jul 28; 33:(7):864–74. doi: 10.4014/jmb.2304.04023. Epub 2023 Jun 12. PMID: 37501379; PMCID: PMC10394337.
     [Google Scholar]
  23. Arsura M, Panta GR, Bilyeu JD, Cavin LG, Sovak MA, Oliver AA, et al. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-(l inhibits AP-1/SMAD signaling and apoptosis: Implications in liver tumor formation. Oncogene. 2003 Jan 23; 22:(3):412–25. doi: 10.1038/sj.onc.1206132.
     [Google Scholar]
  24. Castrillo A, Traves PG, Martin-Sanz P, Parkinson S, Parker PJ, Bosca L . Potentiation of protein kinase C zeta activity by 15-deoxy-delta(12,14) prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages. Mol Cell Biol. 2003 Feb; 23:(4):1196–208. doi: 10.1128/MCB.23.4.1196-1208.2003.
     [Google Scholar]
  25. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 2018;92:4150–4166. doi: 10.1182/blood.V92.11.4150.
     [Google Scholar]
  26. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP . Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999 Oct;5(10):2963–70.
     [Google Scholar]
  27. Wong RSY . Role of Nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention and cancer promotion. Adv Pharmacol Sci. 2019 Jan 31;2019:3418975. doi: 10.1155/2019/3418975. PMID: 30838040; PMCID: PMC6374867.
     [Google Scholar]
  28. Marchetti M, Resnick L, Gamliel E, Kesaraju S, Weissbach H, Binninger D . Sulindac enhances the killing of cancer cells exposed to oxidative stress. PLoS One. 2009 Jun 5; 4:(6):e5804. doi: 10.1371/journal.pone.0005804. PMID: 19503837; PMCID: PMC2686156.
     [Google Scholar]
/content/journals/10.5339/jemtac.2024.absc.10
Loading
The evaluation of the mechanism of interleukin-6 in immune inactivation of oral cancer
Journal of Emergency Medicine, Trauma and Acute Care 2024, 10 (2024); https://doi.org/10.5339/jemtac.2024.absc.10
/content/journals/10.5339/jemtac.2024.absc.10
/content/journals/10.5339/jemtac.2024.absc.10
Loading

Data & Media loading...

Keyword(s): interleukin-6, oral cancer, sulindac and vascular endothelial growth factor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error